iBio (IBIO) Long-Term Deferred Tax (2011 - 2012)
iBio (IBIO) posted quarterly Long-Term Deferred Tax of $8.5 million for Q2 2012, up 37.24% year-over-year from $6.2 million in Q3 2011, and up 37.24% quarter-over-quarter from $6.2 million in Q2 2011.
iBio (IBIO) Long-Term Deferred Tax (2011 - 2012) Analysis & Trends
iBio (IBIO) has reported Long-Term Deferred Tax for 2 consecutive years, with $8.5 million the latest figure, recorded in Q2 2012.
- In Q2 2012, Long-Term Deferred Tax rose 37.24% year-over-year to $8.5 million; the TTM figure through Jun 2012 stood at $8.5 million (up 37.24% YoY), while the FY2012 annual figure was $8.5 million, up 37.24% from the prior year.
- Long-Term Deferred Tax climbed to $8.5 million in Q2 2012 per IBIO's latest filing, from $6.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $8.5 million in Q2 2012 and bottomed at $6.2 million in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 8.53 Mn |
| Jun 30, 2011 | 6.22 Mn |